Promaxo
Oakland, US · Delaware corporation · 4 known investors
Find your way into Promaxo
67 people in our graph share verified history with the Promaxo team — schools, employers, funds. One of them is your warm intro.
Andrea Echstenkamperunlockedknows Amit Vohra · together at University of Florida (overlapped)
×5knows the team · via University of Florida
×6knows the team · via Duke University - The Fuqua School of Business
Promaxo develops a compact, office-based MRI system designed for point-of-care use, with applications including image-guided prostate interventions. The company operates in the medical imaging and medical device sector.
Founders & leadership
AV
Amit VohrainFounder, President & CEOAmit Vohra is an executive officer and director at Promaxo, a medical device company developing a compact, office-based MRI system for point-of-care imaging applications including image-guided interventions. He brings extensive experience in medical device and biotechnology company leadership, product commercialization, and regulatory compliance including FDA and ISO 13485 standards.
MB
Michael BartholomewinEVP & Co-Founder, Inside Director BoD
DK
Dinesh KumarinChief Operations Officer2018–2025
Board
JC
Jonathan ChenBoard director
DH
DC
Dushyant ChipalkattyBoard director
Investors · 4
Reported raises · per SEC filings
Form D private placements$60.9M disclosed across 4 rounds · 2017–2024
▶$41.9MraisedJul 2024 · 163 investors · BiotechnologyRule 506(b)
▶$41.9MraisedJul 2024 · 163 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Amit VohraExecutive Officer, Director
- Michael BartholomewExecutive Officer, Director
- Jonathan ChenDirector
- Derek HenneckeDirector
- Dushyant ChipalkattyDirector
- Dinesh KumarExecutive Officer
- Offering amount
- $57.3M
- Amount sold
- $41.9M
- Minimum investment
- $1
- First sale
- Mar 2024
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$4.2MraisedJan 2021 · 4 investors · BiotechnologyRule 506(b)
▶$4.2MraisedJan 2021 · 4 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Michael BartholomewExecutive Officer, Director
- Jonathan ChenDirector
- Amit VohraExecutive Officer, Director
- Dan McCormickDirector
- Offering amount
- $5M
- Amount sold
- $4.2M
- Minimum investment
- $1
- First sale
- Dec 2020
- Incorporated
- Corporation, Delaware, 2016
- Federal exemptions
- 06b
▶$11MraisedMay 2020 · 69 investors · BiotechnologyRule 506(b)
▶$11MraisedMay 2020 · 69 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Amit VohraExecutive Officer, Director
- Dan McCormickDirector
- Dushyant ChipalkattyDirector
- Michael BartholomewExecutive Officer, Director
- Jonathan ChenDirector
- Offering amount
- $30.6M
- Amount sold
- $11M
- Minimum investment
- $1
- First sale
- May 2020
- Incorporated
- Corporation, Delaware, 2016
- Federal exemptions
- 06b
▶$3.8MraisedSep 2017 · 10 investors · BiotechnologyRule 506(b)
▶$3.8MraisedSep 2017 · 10 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Michael BartholomewExecutive Officer, Director
- Amit VohraExecutive Officer, Director
- Dushyant ChipalkattyDirector
- Offering amount
- $7.6M
- Amount sold
- $3.8M
- Minimum investment
- $1
- First sale
- Sep 2017
- Incorporated
- Corporation, Delaware, 2016
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Competitors · 5
by search overlap
MDxHealth5 shared keywordsMDxHealth is a commercial-stage precision diagnostics company offering molecular diagnostic tests to guide the diagnosis and treatment of prostate cancer and other urologic diseases. Its tests use proprietary genetic, epigenetic, and molecular technologies and serve physicians, patients, payers, and providers.
Cancerresearchuk4 shared keywordsCancer Research UK funds research across discovery, detection, prevention and treatment of cancer to improve patient outcomes and extend survival. It operates as a research funder and scientific organization serving academic and clinical researchers.
Profound Medical3 shared keywordsProfound Medical develops real-time MRI-guided thermal ultrasound systems for incision-free ablation of abnormal or cancerous tissue. The company's TULSA-PRO therapeutic system enables precise ablation of diseased prostate tissue in a commercial-stage medical technology setting.
American Cancer Society (ACS)3 shared keywordsThe American Cancer Society is a nonprofit organization that provides cancer research updates, screening and prevention guidance, and community engagement opportunities. It serves individuals seeking cancer information and those who want to support cancer research and patient advocacy efforts.
Uclahealth3 shared keywordsUCLA Health is a major academic health system providing patient care across five hospitals and 290 clinics in Southern California and the Central Coast, alongside research and medical education. The organization conducts pioneering research in oncology, transplantation, neurosurgery, and other specialties, having contributed to the development of numerous FDA-approved treatments.
Companies competing with Promaxo for the same Google search keywords, organic and paid, via search-intersection analysis.
In the news
Frequently asked questions
- What does Promaxo do?
- Promaxo develops a compact, office-based MRI system designed for point-of-care use, with applications including image-guided prostate interventions. The company operates in the medical imaging and medical device sector.
- Who founded Promaxo?
- Promaxo was founded by Amit Vohra.
- Who are Promaxo's investors?
- Promaxo's investors include Angel Physicians Fund, Band of Angels, Frontier Path VC, Zynext Ventures.
- How much funding has Promaxo raised?
- Promaxo has disclosed $60.9M raised across 4 rounds.
- Where is Promaxo headquartered?
- Promaxo is headquartered in Oakland, US.